SCHEMBL2154394

SCHEMBL2154394

COc1ccccc1-c1c(Cl)sc2c1C(=O)C(C)(c1ccccc1)C(=O)N2

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 11/20 0.50
MAPT P10636 2/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
GSK3B P49841 3/20 0.38
TP53 P04637 1/20 0.37
STK10 O94804 2/20 0.36
SLK Q9H2G2 2/20 0.36
CLK2 P49760 1/20 0.36
GSK3A P49840 1/20 0.36
STK33 Q9BYT3 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
TLK1 Q9UKI8 1/20 0.36
HTR1A P08908 1/20 0.36
DRD1 P21728 1/20 0.36
HTR2A P28223 1/20 0.36
HTR7 P34969 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
APP P05067 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2153158 0.92 HTR6 (0.50) HTR6MAPTMMP2MMP9STK10
SCHEMBL2153898 0.92 HTR6 (0.42) HTR6MAPTGSK3BSTK10SLK
SCHEMBL2153946 0.92 HTR6 (0.42) HTR6GSK3BSTK10SLKCLK2
SCHEMBL2153780 0.89 HTR6 (0.43) HTR6MAPTGSK3BTP53STK10
SCHEMBL2153730 0.89 HTR6 (0.47) HTR6MAPTGSK3BSTK10SLK
SCHEMBL2154073 0.89 HTR6 (0.47) HTR6MAPTMMP2MMP9TP53
SCHEMBL2153958 0.88 HTR6 (0.40) HTR6GSK3BSTK10SLK
SCHEMBL14718107 0.88 STK10 (0.44) HTR6MAPTGSK3BSTK10SLK
SCHEMBL14718511 0.85 MAPT (0.53) HTR6MAPTGSK3BTP53STK10
SCHEMBL14719004 0.85 HTR6 (0.46) HTR6MMP2MMP9HTR1ADRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2519527-B1 THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-12-18 EP claimed
US-20130053401-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-02-28 US claimed
EP-2519527-A1 THIENO [2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF Poxel (FR) 2012-11-07 EP claimed
WO-2011080277-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2011-07-07 WO claimed
US-9365584-B2 Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof POXEL (FR) 2016-06-14 US disclosed
EP-2519527-B1 THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-12-18 EP disclosed
US-20130053401-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-02-28 US disclosed
EP-2519527-A1 THIENO [2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF Poxel (FR) 2012-11-07 EP disclosed
WO-2011080277-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053401-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF PRKAB1, PRKAG1, PRKAB2 HTR6 2378/4885MAPT 3687/4885MMP2 4000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.